消息面上，据银诺医药官微消息，在《"健康中国2030"规划纲要》推动糖尿病防治关口前移、提升创新 药物可及性的战略部署下，中国原研首款超长效人源性GLP-1受体激动剂(GLP-1RA)依苏帕格鲁肽α(商 品名：怡诺轻)正式纳入2025版国家医保药品目录，适用于"成人2型糖尿病患者的血糖控制"，自2026年 1月1日起正式执行。此举标志着我国糖尿病创新治疗普惠化又迈出关键一步。 智通财经APP获悉，银诺医药-B(02591)盘中涨超3%，截至发稿，涨3.43%，报32港元，成交额2074.21 万港元。 在《国家基层糖尿病防治管理指南(2025) 》中，依苏帕格鲁肽ɑ被列为注射类降糖药物的GLP-1RA周制 剂，为基层医疗机构配备和使用该药提供了直接的政策与规范依据。指南强调，对于合并动脉粥样硬化 性心血管疾病(ASCVD)或其风险因素、心力衰竭、慢性肾脏病(CKD)的成人2型糖尿病(T2DM)患者，以 及需要体重管理的超重肥胖患者，GLP-1RA是重要的治疗选择。 ...

每经AI快讯，银诺医药-B(02591.HK)逆市拉升逾23%。截至发稿涨23.38%，报39.44港元，成交额 7649.49万港元。 ...

银诺医药-B(02591)逆市拉升逾24%，入通后两日曾跌超25%。截至发稿，涨23.38%，报39.44港元，成 交额7649.49万港元。 消息面上，近日，银诺医药-B发布公告，根据上海证券交易所及深圳证券交易所分别发出的公告，本公 司H股(H股)获纳入沪港通及深港通(沪港通及深港通)合资格证券名单，自2025年12月8日起生效。董事 会认为，获纳入沪港通及深港通将进一步扩大本公司的投资者基础及增加H股的交易流通量，从而提升 H股的投资价值及本公司于资本市场的声誉。 值得一提的是，据银诺医药官微消息，公司宣布自主研发的超长效GLP-1受体激动剂依苏帕格鲁肽α(怡 诺轻)正式纳入2025年国家医保药品目录，将自2026年1月1日起与新版目录同步实施，为中国2型糖尿病 患者提供更加可及的高质量创新治疗选择。据介绍，依苏帕格鲁肽α(怡诺轻)是国产超长效GLP-1受体激 动剂。具有半衰期长、给药频次低、血糖依赖性调节等特点，是全球第三个、亚洲首个进入商业化阶段 的超长效GLP-1受体激动剂，也是中国本土原创的同类首款创新药物。 ...

Core Viewpoint - Silver诺医药-B (02591) has seen a significant stock price increase of over 24% despite a previous decline of over 25% in the two days following its inclusion in the Hong Kong Stock Connect program, indicating a positive market reaction to recent announcements [1] Group 1: Stock Performance - As of the latest update, Silver诺医药-B's stock price rose by 23.38%, reaching HKD 39.44, with a trading volume of HKD 76.49 million [1] Group 2: Inclusion in Stock Connect - Silver诺医药-B has been included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025 [1] - The board believes that this inclusion will expand the company's investor base and increase the trading liquidity of its H-shares, thereby enhancing the investment value of H-shares and the company's reputation in the capital market [1] Group 3: Product Development - The company announced that its self-developed long-acting GLP-1 receptor agonist, Irsuglutide α (怡诺轻), has been officially included in the National Medical Insurance Drug List for 2025, set to be implemented from January 1, 2026 [1] - Irsuglutide α (怡诺轻) is characterized by a long half-life, low dosing frequency, and blood glucose-dependent regulation, making it the third globally and the first in Asia to enter the commercialization stage among long-acting GLP-1 receptor agonists [1] - This product is also noted as the first innovative drug of its kind developed in China, providing high-quality treatment options for type 2 diabetes patients [1]

Group 1 - The Hang Seng Index fell by 0.84%, down 215 points, closing at 25,549 points, while the Hang Seng Tech Index dropped by 1.32% [1] - The trading volume in the Hong Kong stock market reached HKD 107.8 billion in the morning session [1] - Optical communication stocks surged, driven by increased demand for high-speed optical transceiver modules, with institutions predicting a significant rise in shipment volumes next year [1] Group 2 - Notable gainers included Hongteng Precision, which rose by 7.95%, and Changfei Optical Fiber, which increased by 4.57% [1] - Zhaoyan New Drug saw an increase of over 8% due to a surge in the price of experimental monkeys, with institutions indicating a potential widening supply-demand gap [1] - The stock of Excellence Education, a provider of digital solutions for higher education, rose over 16% on its second day of trading, with its market value approaching HKD 10 billion [1] Group 3 - Oil stocks collectively declined, with geopolitical events weakening support for oil prices, although institutions remain optimistic about the long-term investment value of major oil companies [1] - PetroChina fell by 3%, Sinopec by 2.21%, and CNOOC by 2.32% [1] Group 4 - The non-ferrous metals sector faced significant declines, with Jiangxi Copper down 5.96%, Luoyang Molybdenum down 6.27%, and China Aluminum down 5.34% due to market concerns over central banks' interest rate policies [2] - Silver Noble Pharmaceuticals saw a drop of over 14%, with a cumulative decline of 25% since entering the market [2] Group 5 - Ocean Park Corporation's stock fell by 9%, reaching a new low for the year, amid financial product repayment issues faced by its controlling shareholder [3]

（文章来源：每日经济新闻） 每经AI快讯，银诺医药-B(02591.HK)昨日获纳入港股通后跌超14%，今早继续下挫，累计跌幅达25%。 截至发稿，跌12.73%，报32.9港元，成交额1969.26万港元。 ...

消息面上，上交所、深交所日前发布公告称，因恒生综合中型股指数实施成份股调整，根据有关规定， 港股通标的名单发生调整，将银诺医药调入港股通，自2025年12月8日起生效。此外，银诺医药12月7日 宣布，公司自主研发的超长效GLP-1受体激动剂依苏帕格鲁肽α（怡诺轻 ）正式纳入2025年国家医保药 品目录，将自2026年1月1日起与新版目录同步实施。依苏帕格鲁肽α（怡诺轻 ）是国产超长效GLP-1受 体激动剂。 银诺医药-B(02591)昨日获纳入港股通后跌超14%，今早继续下挫，累计跌幅达25%。截至发稿，跌 12.73%，报32.9港元，成交额1969.26万港元。 ...

智通财经APP获悉，银诺医药-B(02591)昨日获纳入港股通后跌超14%，今早继续下挫，累计跌幅达 25%。截至发稿，跌12.73%，报32.9港元，成交额1969.26万港元。 消息面上，上交所、深交所日前发布公告称，因恒生综合中型股指数实施成份股调整，根据有关规定， 港股通标的名单发生调整，将银诺医药调入港股通，自2025年12月8日起生效。此外，银诺医药12月7日 宣布，公司自主研发的超长效GLP-1受体激动剂依苏帕格鲁肽α（怡诺轻®）正式纳入2025年国家医保 药品目录，将自2026年1月1日起与新版目录同步实施。依苏帕格鲁肽α（怡诺轻®）是国产超长效GLP- 1受体激动剂。 ...

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

Market Overview - The Hong Kong stock market faced pressure, with the Hang Seng Index dropping over 1%, closing at 25,965.36 points, down 1.23% or 319.72 points, with a total turnover of HKD 2,062.3 million [1] - The Hang Seng China Enterprises Index fell by 1.25% to 9,083.53 points, while the Hang Seng Tech Index remained flat at 5,662.55 points [1] Blue Chip Performance - Baidu Group-SW (09888) led blue-chip stocks, rising 3.45% to HKD 125.8, contributing 8.38 points to the Hang Seng Index [2] - Other notable performers included SMIC (00981) up 2.94%, China Ping An (02318) up 2.15%, while China Construction Bank (00939) fell 4.01%, dragging the index down by 54.39 points [2] Sector Highlights - Large tech stocks generally declined, with Alibaba down over 1% and Tencent down 0.82% [3] - Chinese brokerage stocks rose against the trend, with Huatai Securities (06886) up 5.17% and GF Securities (01776) up 3.1% [3] - The light communication sector saw significant gains, with Huiju Technology rising over 7% [4] - Lithium stocks mostly increased, with Ganfeng Lithium (01772) up 6.95% and CATL (03750) up 3.28% [5] Regulatory Developments - The Chairman of the China Securities Regulatory Commission (CSRC) emphasized the need to accelerate the development of top-tier investment banks and institutions, indicating a potential easing of regulations for quality institutions [4] - The CSRC plans to optimize risk control indicators and moderately open up capital space and leverage limits, which could benefit leading brokerages [4] New Listings and Stock Movements - Two new stocks were listed, with Zhuoyue Ruixin (02687) surging 87.26% and Naxinwei (02676) declining 4.31% [7] - Restructured Energy (02570) faced a significant drop of 27.33% on its first trading day after the lock-up period ended [8] - Silver Pharma-B (02591) saw a decline of 14.32% following its inclusion in the Hong Kong Stock Connect [9] - Sutech (02498) performed well, rising 5.23% after securing a major order from FAW Toyota [10] Pharmaceutical Sector Updates - The National Healthcare Security Administration announced the addition of 114 new drugs to the 2025 National Medical Insurance Drug List, with a success rate of 88%, up from 76% in 2024 [6]